Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

The stock's fall snapped a four-day winning streak.

Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

On May 21, analyst Geoff Meacham of Citi maintained a Hold rating on Pfizer Inc. (NYSE:PFE), reiterating the price target of ...

US biotech Tourmaline Bio has reported topline data from a Phase II trial of its lead asset, pacibekitug, in people with chronic kidney disease (CKD) and elevated inflammation levels associated with ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.